|
IMPACTT Newsletter | November 2023
|
|
|
|
|
|
Welcome to our November 2023 IMPACTT newsletter. Keep reading for news, events, and publications in the microbiome world.
|
|
IMPACTT ANNOUNCEMENTS
|
|
|
|
|
Having IMPACTT Symposium
|
Registration & abstract submissions open on Dec 1, 2023 for our Having IMPACTT 4 Symposium, which will be held June 3-5, 2024 at the Malcolm Hotel in Canmore, AB! More details are released all the time, so head to our symposium webpage to sign up for updates and we’ll make sure you don’t miss any deadlines.
|
|
|
|
IMPACTT Mentorship Program
|
Applications are open until Jan 31, 2024 for our IMPACTT Mentorship Program! If you’re a postdoc, research associate, or early career faculty in a microbiome-related field (or know someone who is), this is an excellent opportunity to get paired with an established researcher who can mentor you on your way to new career heights! Learn more and apply here.
|
|
|
|
|
IMPACTT TEAM & NETWORK NEWS
|
|
|
|
|
Clarivate Highly Cited Researchers 2023
|
The following IMPACTT team & network members who were designated Highly Cited Researchers for 2023 by Clarivate: Dr. Kathy McCoy (IMPACTT Director & Platform 1 Lead), Dr. Paul Kubes (Platform 1 Co-Lead), Dr. Jens Walter (IMPACTT Co-Applicant), Dr. Zulfiqar Bhutta (CMI2 Team Grant Lead), and Dr. Arthur Mortha (CMI2 Team Grant Lead). Congratulations!
|
|
|
|
Canada Excellence Research Chair in Immunophysiology and Immunotherapy
|
Dr. Paul Kubes (Platform 1 Co-Lead) has begun a new role at Queen’s University as Canada Excellence Research Chair (CERC) in Immunophysiology and Immunotherapy. The CERC awards are among the most prestigious available gloabally. Read the announcement and the interview with Dr. Kubes in the Queen’s Gazette to learn more about his cutting-edge research. Congratulations!
|
|
|
|
|
|
Postdoctoral Scholar in Microbiome and Child Development
|
The Developmental Psychobiology Lab at the University of Calgary is recruiting a postdoctoral scholar to become part of an active and innovative research program that is elucidating the links between gut microbiota, mental health, neurodevelopment, and health behaviours (sleep, diet, exercise) in children. The scholar’s work will help to identify novel and actionable intervention targets to optimize neurodevelopmental and mental health outcomes in children and adolescents. For more information about this opportunity, please see the job posting, or contact Professor Gerry Giesbrecht at [email protected].
|
|
|
|
|
|
|
Dr. Carolina Tropini (CMI2 Team Grant Lead and IMPACTT Mentor) was interviewed in The Globe and Mail about her lab’s research “investigating the roles and complex interactions of gut microbial communities to discover new therapeutics and combat diseases linked to inflammation.” Read the full article here.
|
|
|
|
|
|
New Publications in the Microbiome World
|
Antonello et al. Scientific Reports. 02 Nov 2023.
|
Highlights: Smoking is a risk factor for many diseases, including respiratory diseases, periodontitis, oropharyngeal cancers, and cardiovascular diseases. Changes in the oral microbiota have also been linked to diseases such as periodontitis, squamous cell carcinomas, and cardiovascular diseases. Smoking is also known to alter the oral microbiota. Therefore, in this study, researchers investigated the influence of smoking on the oral microbiota and predicted metabolic pathways. They found that the oral microbiota of “former smokers” was more similar to “never smokers” than to “current smokers”, especially if they had not smoked in more than 5 years. This included an increase in aerobic bacterial taxa relative abundance in former and never smokers as compared to current smokers, along with inferred nitrate reduction pathways, which affect blood pressure regulation.
|
|
Al et al. Microbiome. 25 Nov 2023.
|
|
Highlights: Kidney stone disease has been increasing in recent years, including among historically less-affected populations such as young women and children. Previous studies have found a link between microbiota dysbiosis and kidney stone formation, but most focused on the gut microbiota. In this study, the researchers compared the gut, urinary, and oral microbiota of 83 participants who regularly produce kidney stones and 30 healthy controls. Urinary oxalate levels were lower in healthy controls compared to stone formers. The production of oxalate is implicated in the formation of kidney stones, and specific Oxalobacter spp. (such as O. formigenes) have previously been thought to play a role in protecting against kidney stone formation since they use oxalate as a sole carbon source. Stone formers and healthy controls had significantly different gut, but not oral, microbiota composition and alpha diversity. However, no differences in the relative abundance of O. formigenes were identified by whole shotgun metagenomic sequencing. The researchers suggest that the historical focus on Oxalobacter spp. may provide an incomplete picture of kidney stone disease risk.
|
|
|
|
New Publications from our IMPACTT Team and Network
|
Dr. Anita Kozyrskyj (Platform 2 Lead) & Dr. Gerald Giesbrecht (CMI2 Team Grant Lead)
|
Evanchuk et al. The Journal of Nutrition. 19 Nov 2023.
|
|
Dr. Wendy Lou & Dr. Padmaja Subbarao (CMI2 Team Grant Leads)
|
Lu et al. Journal of the Royal Statistical Society Series C: Applied Statistics. 13 Nov 2023.
|
|
Dr. Aleixo Muise & Dr. Anne Griffiths (CMI2 Team Grant Leads)
|
Stallard et al. Gastro Hep Advances. 18 Nov 2023.
|
|
Dr. Marie-Claire Arrieta (Platform 2 Co-Lead)
|
Glatthardt et al. The Journal of Allergy and Clinical Immunology. 18 Oct 2023.
|
|
Dr. Braedon McDonald (Education Co-Lead)
|
Chiu et al. Cell Stress and Chaperones. 15 Nov 2023.
|
|
Dr. Diego Silva (Ethics Lead)
|
Fehross et al. Journal of Bioethical Inquiry. 08 Nov 2023.
|
|
Dr. Benjamin Willing (IMPACTT Co-Applicant)
|
Prisnee et al. Applied and Environmental Microbiology. 30 Oct 2023.
|
|
Dr. Eytan Wine (IMPACTT Co-Applicant)
|
Boneh et al. Inflammatory Bowel Diseases. 18 Nov 2023.
|
|
Dr. Vanessa Poliquin (CMI2 Team Grant Lead)
|
San Juan Galán et al. PLOS Pathogens. 10 Nov 2023.
|
|
Dr. Michael Surette (CMI2 Team Grant Lead)
|
Svishchuk et al. Antimicrobial Agents and Chemotherapy. 15 Nov 2023.
|
|
Dr. Carolina Tropini (CMI2 Team Grant Lead)
|
Tropini et al. mBio. 17 Nov 2023.
|
|
Dr. Emma Allen-Vercoe (CMI2 Team Grant Lead)
|
Pay et al. Food and Chemical Toxicology. 26 Nov 2023.
|
|
Dr. Gerald Giesbrecht (CMI2 Team Grant Lead)
|
England-Mason et al. Children. 25 Nov 2023.
|
|
Dr. Jeremy Hirota (CMI2 Team Grant Lead)
|
Vukmirovic et al. Annals of the American Thoracic Society. 30 Oct 2023.
|
Carpio et al. ACS Applied Material Interfaces. 14 Nov 2023.
|
|
Dr. Wendy Lou (CMI2 Team Grant Lead)
|
Li et al. University of Toronto Journal of Public Health. 30 Oct 2023.
|
|
Dr. David Mack (CMI2 Team Grant Lead)
|
Gillmore et al ACG Case Reports Journal. 03 Nov 2023.
|
|
Dr. André Marette (CMI2 Team Grant Lead)
|
Liu et al. The FASEB Journal. 30 Oct 2023.
|
Morissette et al. American Journal of Physiology – Endocrinology and Metabolism. 17 Nov 2023.
|
|
Dr. Roger Paredes (CMI2 Team Grant Lead)
|
Elizalde-Torrent et al. Vaccines. 30 Oct 2023.
|
Santos et al. Open Forum Infectious Diseases. 31 Oct 2023.
|
Lladós et al. Clinical Microbiology and Infection. 18 Nov 2023.
|
Kostka et al. Nature Communications. 17 Nov 2023.
|
|
Gottlieb & Paredes. The Lancet Infectious Diseases. 22 Nov 2023.
|
|
|
UPCOMING EVENTS AND REMINDERS
|
|
|
|
|
Click here to see curated lists of upcoming events in the microbiome world
|
|
|
IMPACTT Microbiome Standards
|
Our four Microbiome Standards are ready to ship across Canada and internationally, and they’re FREE for Canadian labs. (Not in Canada? Just pay shipping.) Click here to learn more and sign up to receive your standards.
|
|
|
|
|
Be a contributor to our microbiome community!
|
|
|
|
|
|
|
Follow @IMPACTT on Mastodon and tag us to share your news!
|
|
|
|
Subscribe to our YouTube channel:
|
|
|
|
|
|
|
|
|
|
